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Most small renal tumours that enhance on CT and MRI are renal cell 
carcinomas. They are usually discovered incidentally. The rate of 
detection is increasing by 3-4% per year,in parallel with the increased 
use of cross-sectional imaging. Approximately 25-30% of surgically 
removed small renal masses are benign; 55-60% are indolent renal cell 
carcinomas, and only 20-25% have potentially aggressive features, 
defined by high nuclear grade locally invasive characteristics. 
Small renal tumours are often observed rather than operated on 
immediately, because they are relatively benign, and few 
metastasize. There have been no documented reports of disease 
progression in the absence of demonstrable tumour growth. As the 
incidence of small renal tumour has increased, so has the performance 
of surgery. However,the increased rate of surgery has not been 
translated into improved survival. Therefore, it is time to reassess the 
appropriateness of extirpative surgery for these small masses. 
The policy of observing small renal tumours also has to be seriously 
questioned, because lack of growth does not implicate benignity, 70% 
of tumours grow under surveillance and 40% of patients cross over to 
resection during observation. Nephron-sparing treatment of small 
neoplasms includes partial nephrectomy, thermal ablation and 
cryotherapy. Percutaneous ablation is usually carried out under CT 
guidance.The main implications are solitary kidney, renal 
insufficiency, and multiple tumours, as surgery is particularly 
problematic in these groups of patients. Ten per cent of patients with 
solitary kidneys and chronic kidney disease who have partial 
nephrectomy, progress to renal failure. In a series of 23 tumours in 
solitary kidneys treated with radiofrequency at Guy’s and St. Thomas’ 
Hospital, London, there were four local recurrences, which were 
subsequently treated successfully. There was no significant difference 
between the baseline glomerular filtration rate and the GRF at 3, 12 
and 24 months. None of the patients required haemodialysis. 
Percutaneous cryotherapy is similarly successful, and has a very low 
recurrence rate. 
Taking into consideration the very low morbidity of percutaneous 
thermal ablation and cryotherapy, the time has probably come to 
abandon the policy of observation of small renal tumours in most 
patients with this condition.    
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Image guided percutaneous radiofrequency ablation of lung cancer is a 
thermal destruction of small primary and metastatic lung tumors. 
Since, its first use in 2000, numerous reports have demonstrated 
safety and low invasiveness of the technique, rendering possible to 
treat non surgical candidates, namely with limited pulmonary function 
or other comorbidities. Indeed, several studies have demonstrated no 
changes in respiratory function in short or long term. 
Complete ablation has been demonstrated in 100% of pathologic 
studies obtained after radiofrequency ablation of 9 lung metastases 
measuring 3cm or less. The reported local success rate of ablation is 
around 90% in a review paper, with even better results for tumor 
below 2 cm. There is no difference demonstrated in local efficacy in 
between primary NSLC and lung metastases. Overall survival of 
treated patient with NSCLC is in between 55 and 60% at 4 years in 
most recent studies. For colorectal metastasis, a 70% 3-years overall 
survival is achieved. However, even if survival data are encouraging, 
improvement of survival after thermal ablationis hard to demonstrate.  
Even if some data exists on the synergy of combination of radiation 
therapy and radiofrequency ablation, they need to be refined.  
Consequently today SBRT and thermal ablation challenge the same 
population of non-surgical candidate and data are lacking to 
demonstrate superiority of one technique over the other.  
Today both SBRT and radiofrequency ablation are limited to non-
surgical candidates. A challenge of the future is to determine a 
subpopulation of patients that can benefit from thermal ablation or 
SBRT instead of surgery, and still achieved the same survival with 
improved quality of life and lower morbidity. Patients that benefit 
today from wedge resection without lymphnode resection are 
probably the target population, including both very early stage NSCLC 
and metastases of small size. 
Combination of both SBRT and thermal ablation should be evaluated in 
tumor of larger size because size increase predictive factor of 
incomplete treatment for both SBRT and radiofrequency ablation. 
Both SBRT and thermal ablation are sharing some difficulties in follow-
up imaging because the tumor does not shrunk or disappear in the 
early stage after trea tment.Improvement in follow-up imaging are 
needed and this effort in improving imaging technique and criteria for 
response evaluation could be easily shared in between radiation 
therapist and interventional oncologists through the use of functional 
imaging.  
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Surgery is the mainstay of liver cancer treatment. Resection and 
transplantation compete as the first-line option in patients with early-
stage hepatocellular carcinoma (HCC) on an intention-to-treat 
perspective, and achieve the best survival outcomes in well-selected 
candidates. RFA is the most common treatment offered to early-stage 
HCC patients who have been rejected for surgery. Recent reports on 
long-term outcomes of RFA-treated patients have shown that in 
patients with Child-Pugh class A and early-stage HCC, 5-year survival 
rates range 50-60%. Therefore, an open question is whether RFA can 
compete with surgical resection as first-line treatment. Two 
randomized controlled trials have been reported with opposite 
results. Thus, at this point there is no unequivocal data to back up 
RFA as a replacement of resection as first-line treatment for patients 
with early-stage HCC. While complete removal of neoplastic tissue 
(“R0” resection) is common after surgery for early-stage HCC, studies 
in which the pathological specimens of tumors ablated with RFA were 
analyzed have shown non-negligible rates of incomplete response. Is 
RFA the best technique for tumor ablation in 2013? Several novel 
alternate options are currently being explored. These methods – 
including microwave ablation, cryoablation, and irreversible 
electroporation (IRE) among others – claim to be able to overcome 
some of the limitations of RFA. Non-thermal techniques such as IRE 
have attracted attention, since the issues associated with perfusion-
mediated tissue cooling or heating are not relevant. Despite the 
progress in surgical and ablation techniques, the long-term prognosis 
of patients with early-stage HCC remains unsatisfactory compared 
with other common human cancers because of a high recurrence rate. 
Most resection and ablation series in the literature report a 5-year 
recurrence rate in excess of 70%, which is the main cause of death. A 
large trial in which the systemically active, molecular targeted drug 
sorafenib is used after successful resection or ablation is on-going. 
The outcomes of this trial are eagerly awaited, as it has the potential 
to establish, for the first time, an effective adjuvant regimen to 
improve recurrence-free survival. 
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Cancer is a major cause of death and morbidity world-wide. It often 
has a chronic course and the traditional means of treating cancer - 
surgery, radiation treatment and chemotherapy can in themselves be 
toxic and cause significant side effects both short and longterm. 
Cancer and its treatment can result not only in mortality and 
morbidity, but it imparts a great personal and societal economic 
burden. The world wide cost of cancer in 2009 was estimated to be 
US$305 billion with 53% being direct medical costs and 24% due to lost 
income(1). 
The traditional method of assessing tumour response with the RECIST 
criteria, developed initially in 2000 by the NCI, the NCIC clinical trials 
group and the EORTC, has been invaluable in producing a set of 
published rules that define whether target lesions improve (respond), 
stay the same (stable) or worsen (progressive)(2). More recently in 
some tumour sites the use of functional PET imaging has shown high 
predictive value in treatment outcome. 
To assess the holistic impact of cancer and treatment however, other 
methods of assessment are required and are of critical and at times 
perhaps of overriding importance. Assessing the overall benefit - have 
